Assuntos
Alérgenos/imunologia , Anafilaxia/diagnóstico , Meios de Contraste/administração & dosagem , Hipersensibilidade a Drogas/diagnóstico , Face/patologia , Gadolínio/administração & dosagem , Meglumina/análogos & derivados , Compostos Organometálicos/administração & dosagem , Adulto , Anafilaxia/etiologia , Anafilaxia/prevenção & controle , Angioedema , Difenidramina/uso terapêutico , Hipersensibilidade a Drogas/complicações , Hipersensibilidade a Drogas/tratamento farmacológico , Feminino , Gadolínio/imunologia , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Humanos , Imageamento por Ressonância Magnética , Meglumina/administração & dosagem , Meglumina/imunologia , Compostos Organometálicos/imunologia , Testes Cutâneos , Síncope , UrticáriaRESUMO
Forty-four adult patients with cutaneous leishmaniasis (CL) were enrolled in a randomized, double-blind, controlled, dose-escalating clinical trial and were randomly assigned to receive three injections of either the LEISH-F1+MPL-SE vaccine (consisting of 5, 10, or 20 µg recombinant Leishmania polyprotein LEISH-F1 antigen+25 µg MPL-SE adjuvant) (n=27), adjuvant alone (n=8), or saline placebo (n=9). The study injections were given subcutaneously on Days 0, 28, and 56, and the patients were followed through Day 336 for safety, immunological, and clinical evolution endpoints. All patients received chemotherapy with meglumine antimoniate starting on Day 0. The vaccine was safe and well tolerated. Nearly all vaccine recipients and no adjuvant-alone or placebo recipients demonstrated an IgG antibody response to LEISH-F1 at Day 84. Also at Day 84, 80% of vaccine recipients were clinically cured, compared to 50% and 38% of adjuvant-alone and placebo recipients. The LEISH-F1+MPL-SE vaccine was safe and immunogenic in CL patients and appeared to shorten their time to cure when used in combination with meglumine antimoniate chemotherapy.
Assuntos
Leishmaniose Cutânea/terapia , Meglumina/administração & dosagem , Compostos Organometálicos/administração & dosagem , Vacinas Protozoárias/imunologia , Adjuvantes Imunológicos/administração & dosagem , Adolescente , Adulto , Anticorpos Antiprotozoários/sangue , Formação de Anticorpos , Antígenos de Protozoários/imunologia , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Humanos , Imunoglobulina G/sangue , Leishmaniose Cutânea/imunologia , Masculino , Meglumina/imunologia , Antimoniato de Meglumina , Pessoa de Meia-Idade , Compostos Organometálicos/imunologia , Poliproteínas/imunologia , Vacinas Protozoárias/efeitos adversos , Proteínas Recombinantes/imunologia , Adulto JovemRESUMO
BACKGROUND: Gadolinium chelates are relatively safe contrast media used in MRI. Immediate severe adverse effects are exceptionally rare and mostly concern mild anaphylactoid reactions. We report a case of anaphylaxis to gadobenate dimeglumine (Gd-BOPTA, Multihance), a gadolinium-based contrast agent. METHODS: A 32-year-old female patient with a personal history of multiple sclerosis, while undergoing an MRI scan, developed bronchospasm and acute urticaria with diffuse giant pruritic plaques in the first minute of Gd-BOPTA infusion. The procedure was cancelled and acute treatment of the reaction took place. The patient reported 2 additional MRI scans with definite use of unknown contrast media in the past 2 years without any adverse effect. Blood samples were obtained 2 and 48 h after the reaction for measurement of serum tryptase concentration (Pharmacia Diagnostics, Uppsala, Sweden). Skin prick tests and intradermal tests were performed using 1:1,000, 1:100 and 1:10 dilution of the offending agent and alternative gadolinium-based agents [gadodiamide (Omniscan) and gadoteric acid (Dotarem)]. A group of 10 nonatopic individuals who underwent the same skin testing comprised the control group. RESULTS: Tryptase concentration was highly elevated 2 h after the reaction (21 microg/l) compared with that at 48 h (3 microg/l). Skin prick tests in our patient were all negative, while intradermal testing with 0.03 ml of 1:100 and 1:10 preparations of Multihance showed a definite positive wheal-and-flare reaction. Skin tests to the alternative agents showed no response. In the control group, all performed tests were negative. CONCLUSION: We report the first case of an allergic reaction to gadobenate dimeglumine. Besides, skin testing seems to be a precious diagnostic tool which, if positive, strongly suggests a mast cell-mediated underlying mechanism.